Browse studies

Find your next paid study

5 recruiting studies matching your filters

Phase II Trial of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is …

AdenocarcinomaProstate CancerNeoplasms+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07574541

Phase 1

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumo…

Neoplasms, BrainGlioblastoma MultiformeGlioblastoma of Cerebellum+30 more

Estimated

~$10 – $6,250

Phase 1

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractor…

Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more

Estimated

~$10 – $8,750

Kelonia Therapeutics, Inc.NCT07075185

Phase 1

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute m…

AMLAML With Mutated NPM1Hematologic Malignancy+9 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT06001788

Phase 1

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cel…

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more

Estimated

~$10 – $8,750

OriCell Therapeutics Co., Ltd.NCT06271252